Health
New VERTIS-CV data: Kidney function preserved with ertugliflozin in type 2 diabetes – Healio
New exploratory analyses show treatment with the SGLT2 inhibitor ertugliflozin reduced risk for worsening kidney function, dialysis or renal death among adults with type 2 diabetes compared with placebo.In prespecified exploratory analyses presented at the vi…
Source/Disclosures
Source: Cherney D. VERTIS-CV Outcome. Presented at: EASD Annual Meeting; Sept. 21-25, 2020 (virtual meeting).
Disclosures:
Merck and Pfizer sponsored VERTIS-CV. Cannon reports he has received research grants or honoraria from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia, Daiichi Sankyo, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer and Sanofi. Cherney reports he has received consultant f…
-
General17 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News17 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General24 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
General19 hours agoPerth man charged after investigation into organised crime and tobacco store attacks